Eczema drug upadacitinib under Real-World safety check in china
NCT ID NCT05959083
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how safe and effective upadacitinib is for Chinese adolescents and adults with moderate to severe atopic dermatitis (eczema). About 200 participants will take the drug as prescribed by their doctor and be followed for up to 24 months. The goal is to track serious infections and other side effects in real-world use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
upadacitinib
What this could lead to
If successful, this could confirm that upadacitinib is a safe and effective option for managing moderate to severe atopic dermatitis in Chinese patients.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only includes Chinese patients, so findings may not apply to other populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chengdu Second Municipal People's Hospital /ID# 257732
Chengdu, Sichuan, 610017, China
-
Dermatology Hospital of Southern Medical University /ID# 261862
Guangzhou, Guangdong, 510091, China
-
First Affiliated Hospital of China Medical University /ID# 257641
Shenyang, Liaoning, 110001, China
-
Hangzhou First People's Hospital /ID# 261867
Hangzhou, Zhejiang, 310003, China
-
Huashan Hospital, Fudan University /ID# 256456
Shanghai, Shanghai Municipality, 200040, China
-
Ningbo First Hospital /ID# 263884
Ningbo, Zhejiang, 315010, China
-
Peking University Third Hospital /ID# 257722
Beijing, Beijing Municipality, 100191, China
-
People's Hospital of Henan Province /ID# 257736
Zhengzhou, Henan, 450003, China
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 257726
Shanghai, Shanghai Municipality, 200065, China
-
Second Affiliated Hospital of Xian Jiaotong University /ID# 257733
Xi'an, Shaanxi, 710004, China
-
Shandong Dermatological Hospital /ID# 257727
Jinan, Shandong, 250022, China
-
Shanghai Skin Disease Hospital /ID# 257719
Shanghai, Shanghai Municipality, 200443, China
-
Sichuan Provincial People's Hospital /ID# 263898
Chengdu, Sichuan, 610072, China
-
The Eighth Affiliated Hospital, Sun Yat-sen universtiy /ID# 257737
Shenzhen, Guangdong, 518033, China
-
The First Affiliated Hospital Of Fujian Medical University /ID# 257725
Fuzhou, Fujian, 350005, China
-
The Second Affiliated Hospital of Zhejiang University School of Medicine /ID# 257723
Hangzhou, Zhejiang, 310009, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 257724
Wuhan, Hubei, 430022, China
-
West China Hospital, Sichuan University /ID# 257720
Chengdu, Sichuan, 610041, China